JP6652497B2 - 組換え単純ヘルペスウィルス２（ｈｓｖ−２）ワクチンベクター - Google Patents
組換え単純ヘルペスウィルス２（ｈｓｖ−２）ワクチンベクター Download PDFInfo
- Publication number
- JP6652497B2 JP6652497B2 JP2016555659A JP2016555659A JP6652497B2 JP 6652497 B2 JP6652497 B2 JP 6652497B2 JP 2016555659 A JP2016555659 A JP 2016555659A JP 2016555659 A JP2016555659 A JP 2016555659A JP 6652497 B2 JP6652497 B2 JP 6652497B2
- Authority
- JP
- Japan
- Prior art keywords
- hsv
- glycoprotein
- virus
- vaccine
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000701074 Human alphaherpesvirus 2 Species 0.000 title claims description 415
- 229960005486 vaccine Drugs 0.000 title claims description 86
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 120
- 208000015181 infectious disease Diseases 0.000 claims description 77
- 210000002845 virion Anatomy 0.000 claims description 74
- 210000004027 cell Anatomy 0.000 claims description 71
- 108090000623 proteins and genes Proteins 0.000 claims description 63
- 102000003886 Glycoproteins Human genes 0.000 claims description 62
- 108090000288 Glycoproteins Proteins 0.000 claims description 62
- 101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 claims description 41
- 102100022717 Atypical chemokine receptor 1 Human genes 0.000 claims description 38
- 239000000232 Lipid Bilayer Substances 0.000 claims description 37
- 239000008194 pharmaceutical composition Substances 0.000 claims description 33
- 241000700584 Simplexvirus Species 0.000 claims description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 31
- 108010090054 Membrane Glycoproteins Proteins 0.000 claims description 30
- 102000012750 Membrane Glycoproteins Human genes 0.000 claims description 30
- 201000010099 disease Diseases 0.000 claims description 30
- 239000000427 antigen Substances 0.000 claims description 24
- 108091007433 antigens Proteins 0.000 claims description 24
- 102000036639 antigens Human genes 0.000 claims description 24
- 208000037952 HSV-1 infection Diseases 0.000 claims description 16
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 15
- 210000004392 genitalia Anatomy 0.000 claims description 14
- 230000028993 immune response Effects 0.000 claims description 12
- 108700019146 Transgenes Proteins 0.000 claims description 11
- 244000045947 parasite Species 0.000 claims description 11
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 5
- 208000025865 Ulcer Diseases 0.000 claims description 5
- 238000012217 deletion Methods 0.000 claims description 5
- 230000037430 deletion Effects 0.000 claims description 5
- 231100000397 ulcer Toxicity 0.000 claims description 5
- 230000001580 bacterial effect Effects 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 210000000170 cell membrane Anatomy 0.000 claims description 3
- 241000700605 Viruses Species 0.000 description 80
- 238000000034 method Methods 0.000 description 61
- 241000699670 Mus sp. Species 0.000 description 49
- 239000000203 mixture Substances 0.000 description 47
- 206010042566 Superinfection Diseases 0.000 description 42
- 210000001744 T-lymphocyte Anatomy 0.000 description 31
- 230000003053 immunization Effects 0.000 description 28
- 150000007523 nucleic acids Chemical class 0.000 description 23
- 230000001717 pathogenic effect Effects 0.000 description 23
- 241000725303 Human immunodeficiency virus Species 0.000 description 22
- 108020004707 nucleic acids Proteins 0.000 description 22
- 102000039446 nucleic acids Human genes 0.000 description 22
- 238000002649 immunization Methods 0.000 description 21
- 208000001688 Herpes Genitalis Diseases 0.000 description 17
- 201000004946 genital herpes Diseases 0.000 description 17
- 101900228213 Human herpesvirus 2 Envelope glycoprotein D Proteins 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 12
- 101150036031 gD gene Proteins 0.000 description 11
- 244000052769 pathogen Species 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 230000003612 virological effect Effects 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 10
- 230000010076 replication Effects 0.000 description 10
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 9
- 101150096955 US6 gene Proteins 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 210000003594 spinal ganglia Anatomy 0.000 description 9
- 230000005867 T cell response Effects 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 8
- 210000001165 lymph node Anatomy 0.000 description 8
- 230000003472 neutralizing effect Effects 0.000 description 8
- 238000007920 subcutaneous administration Methods 0.000 description 8
- 210000003501 vero cell Anatomy 0.000 description 8
- 230000000890 antigenic effect Effects 0.000 description 7
- 201000008827 tuberculosis Diseases 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 230000002238 attenuated effect Effects 0.000 description 6
- 230000005540 biological transmission Effects 0.000 description 6
- 239000013592 cell lysate Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000002458 infectious effect Effects 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 230000009885 systemic effect Effects 0.000 description 6
- 241000711950 Filoviridae Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 231100000518 lethal Toxicity 0.000 description 5
- 230000001665 lethal effect Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 229940031626 subunit vaccine Drugs 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 241000700198 Cavia Species 0.000 description 4
- 101710094648 Coat protein Proteins 0.000 description 4
- 206010073931 Genital herpes simplex Diseases 0.000 description 4
- 241000186362 Mycobacterium leprae Species 0.000 description 4
- 241000187492 Mycobacterium marinum Species 0.000 description 4
- 241000187917 Mycobacterium ulcerans Species 0.000 description 4
- 208000012902 Nervous system disease Diseases 0.000 description 4
- 208000025966 Neurological disease Diseases 0.000 description 4
- 230000005875 antibody response Effects 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 230000007420 reactivation Effects 0.000 description 4
- 230000000306 recurrent effect Effects 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 210000000427 trigeminal ganglion Anatomy 0.000 description 4
- 241000337692 Bunia Species 0.000 description 3
- 235000013049 Bunias Nutrition 0.000 description 3
- 101710132601 Capsid protein Proteins 0.000 description 3
- 241000606161 Chlamydia Species 0.000 description 3
- 208000003322 Coinfection Diseases 0.000 description 3
- 241000709661 Enterovirus Species 0.000 description 3
- 101800000342 Glycoprotein C Proteins 0.000 description 3
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 3
- 206010023927 Lassa fever Diseases 0.000 description 3
- 101710125418 Major capsid protein Proteins 0.000 description 3
- 241000018377 Methylococcaceae bacterium Species 0.000 description 3
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 3
- 101710141454 Nucleoprotein Proteins 0.000 description 3
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 3
- 101710083689 Probable capsid protein Proteins 0.000 description 3
- 241000711798 Rabies lyssavirus Species 0.000 description 3
- 241000724205 Rice stripe tenuivirus Species 0.000 description 3
- 238000011579 SCID mouse model Methods 0.000 description 3
- 241000282898 Sus scrofa Species 0.000 description 3
- 230000024932 T cell mediated immunity Effects 0.000 description 3
- 101710187780 Tumor necrosis factor receptor superfamily member 14 Proteins 0.000 description 3
- 108010067390 Viral Proteins Proteins 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- 241000712461 unidentified influenza virus Species 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 210000001215 vagina Anatomy 0.000 description 3
- 230000001018 virulence Effects 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010010099 Combined immunodeficiency Diseases 0.000 description 2
- 241001115402 Ebolavirus Species 0.000 description 2
- 208000022555 Genital disease Diseases 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102100034349 Integrase Human genes 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- 206010065764 Mucosal infection Diseases 0.000 description 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 2
- 208000020241 Neonatal disease Diseases 0.000 description 2
- 208000037129 Newborn Diseases Infant Diseases 0.000 description 2
- 101710186352 Probable membrane antigen 3 Proteins 0.000 description 2
- 101710181078 Probable membrane antigen 75 Proteins 0.000 description 2
- 101710178472 Tegument protein Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003622 anti-hsv Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000012224 gene deletion Methods 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 230000003832 immune regulation Effects 0.000 description 2
- 210000004201 immune sera Anatomy 0.000 description 2
- 229940042743 immune sera Drugs 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000010197 meta-analysis Methods 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 206010040872 skin infection Diseases 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 229940125575 vaccine candidate Drugs 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 244000052613 viral pathogen Species 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- NGGRGTWYSXYVDK-RRKCRQDMSA-N 4-amino-5-chloro-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound C1=C(Cl)C(N)=NC(=O)N1[C@@H]1O[C@H](CO)[C@@H](O)C1 NGGRGTWYSXYVDK-RRKCRQDMSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 241000867607 Chlorocebus sabaeus Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 102000008016 Eukaryotic Initiation Factor-3 Human genes 0.000 description 1
- 108010089790 Eukaryotic Initiation Factor-3 Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 206010048461 Genital infection Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 102000011786 HLA-A Antigens Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 208000000903 Herpes simplex encephalitis Diseases 0.000 description 1
- 208000037018 Herpes simplex virus encephalitis Diseases 0.000 description 1
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 1
- 208000000440 Herpetic Stomatitis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000840258 Homo sapiens Immunoglobulin J chain Proteins 0.000 description 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100029571 Immunoglobulin J chain Human genes 0.000 description 1
- 208000032754 Infant Death Diseases 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000187480 Mycobacterium smegmatis Species 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010067152 Oral herpes Diseases 0.000 description 1
- 101710188053 Protein D Proteins 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 101710132893 Resolvase Proteins 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010029389 Simplexvirus glycoprotein B Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 241000589884 Treponema pallidum Species 0.000 description 1
- 101150053996 UL47 gene Proteins 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical group N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000028956 calcium-mediated signaling Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000005101 cell tropism Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000014564 chemokine production Effects 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000001113 coital effect Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000004041 dendritic cell maturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000011554 guinea pig model Methods 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 229940124725 herpes simplex vaccine Drugs 0.000 description 1
- 201000010884 herpes simplex virus keratitis Diseases 0.000 description 1
- 230000000423 heterosexual effect Effects 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 210000000688 human artificial chromosome Anatomy 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000008684 selective degradation Effects 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 208000013464 vaginal disease Diseases 0.000 description 1
- 230000005570 vertical transmission Effects 0.000 description 1
- 230000007502 viral entry Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
- C07K16/087—Herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16661—Methods of inactivation or attenuation
- C12N2710/16662—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16671—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461946965P | 2014-03-03 | 2014-03-03 | |
| US61/946,965 | 2014-03-03 | ||
| US201462080663P | 2014-11-17 | 2014-11-17 | |
| US62/080,663 | 2014-11-17 | ||
| PCT/US2015/018272 WO2015134368A2 (en) | 2014-03-03 | 2015-03-02 | Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020009043A Division JP6844045B2 (ja) | 2014-03-03 | 2020-01-23 | 組換え単純ヘルペスウィルス２（ｈｓｖ−２）ワクチンベクター |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017510262A JP2017510262A (ja) | 2017-04-13 |
| JP2017510262A5 JP2017510262A5 (enExample) | 2018-04-12 |
| JP6652497B2 true JP6652497B2 (ja) | 2020-02-26 |
Family
ID=54055977
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016555659A Active JP6652497B2 (ja) | 2014-03-03 | 2015-03-02 | 組換え単純ヘルペスウィルス２（ｈｓｖ−２）ワクチンベクター |
| JP2020009043A Active JP6844045B2 (ja) | 2014-03-03 | 2020-01-23 | 組換え単純ヘルペスウィルス２（ｈｓｖ−２）ワクチンベクター |
| JP2021026943A Active JP7050193B2 (ja) | 2014-03-03 | 2021-02-24 | 組換え単純ヘルペスウィルス２（ｈｓｖ－２）ワクチンベクター |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020009043A Active JP6844045B2 (ja) | 2014-03-03 | 2020-01-23 | 組換え単純ヘルペスウィルス２（ｈｓｖ−２）ワクチンベクター |
| JP2021026943A Active JP7050193B2 (ja) | 2014-03-03 | 2021-02-24 | 組換え単純ヘルペスウィルス２（ｈｓｖ－２）ワクチンベクター |
Country Status (7)
| Country | Link |
|---|---|
| US (5) | US9999665B2 (enExample) |
| EP (2) | EP3113801B1 (enExample) |
| JP (3) | JP6652497B2 (enExample) |
| CN (2) | CN106456805B (enExample) |
| AU (2) | AU2015225499B2 (enExample) |
| CA (1) | CA2942166A1 (enExample) |
| WO (1) | WO2015134368A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015134368A2 (en) * | 2014-03-03 | 2015-09-11 | Albert Einstein College Of Medicine Of Yeshiva University | Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors |
| US10918712B2 (en) * | 2014-03-03 | 2021-02-16 | Albert Einstein College Of Medicine | Passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors |
| CN119523873A (zh) | 2018-04-27 | 2025-02-28 | 克里斯托生物技术股份有限公司 | 用于美容性应用的编码一种或多种美容蛋白的重组核酸 |
| WO2019213305A1 (en) * | 2018-05-01 | 2019-11-07 | Albert Einstein College Of Medicine | HSV-2-DELTA-gD VACCINES AND METHODS FOR THEIR PRODUCTION AND USE |
| WO2020056411A1 (en) * | 2018-09-14 | 2020-03-19 | Excell Biotech, Llc | Recombinant herpes simplex virus 1 (hsv-1) |
| IL282135B2 (en) * | 2018-10-17 | 2025-06-01 | Albert Einstein College Medicine | Method of enhancing antibody-dependent cell-mediated cytotoxicity (adcc |
| JP2022517322A (ja) * | 2019-01-03 | 2022-03-08 | アルベルト・アインシュタイン・カレッジ・オブ・メディシン | 組み換え単純ヘルペスウイルス２（ｈｓｖ－２）ワクチンベクターを使用する免疫の受動伝達 |
| CA3179416A1 (en) * | 2020-04-07 | 2021-10-14 | Albert Einstein College Of Medicine | Method of treating and preventing ocular disease with hsv-2 delta gd |
| IL298288B2 (en) * | 2020-05-29 | 2025-03-01 | Albert Einstein College Medicine | Methods for using Delta-gD of single-stranded HSV-2 virus and recombinant HSV-2 glycoprotein D |
| CN116615533A (zh) | 2020-09-24 | 2023-08-18 | 阿尔伯爱因斯坦医学院 | Attb细胞系、源自其的转基因细胞系及其制备方法 |
| WO2023245159A1 (en) * | 2022-06-16 | 2023-12-21 | Albert Einstein College Of Medicine | Recombinant herpes simplex virus 2 (hsv-2) vectors and engineered transgenic vero cell lines |
| EP4565270A4 (en) * | 2022-08-05 | 2025-11-19 | Immvira Biopharmaceuticals Co Ltd | HERPES SIMPLEX VIRUS TYPE 1 VACCINE INCOMPETENT FOR REPLICATION |
| US20250222112A1 (en) * | 2022-10-14 | 2025-07-10 | Arizona Board Of Regents On Behalf Of Arizona State University | Recombinant immune complexes targeting herpes simplex virus |
| WO2025231288A2 (en) | 2024-05-01 | 2025-11-06 | Viradigm, Inc. | Hsv vectors having improved safety profiles |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT77014B (en) * | 1982-07-20 | 1986-01-24 | Molecular Genetics Inc | Production of herpes simplex viral proteins |
| NZ209308A (en) * | 1983-08-30 | 1991-08-27 | Genentech Inc | Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein |
| AU591145B2 (en) * | 1985-07-29 | 1989-11-30 | Pharmacia & Upjohn Company | Virus vaccine with deletion of an antigen of the wild-type virus |
| US5646041A (en) * | 1987-02-12 | 1997-07-08 | Harfeldt; Elisabeth | Monoclonal antibody to herpes simplex virus and cell line producing same |
| AU696336B2 (en) * | 1993-03-19 | 1998-09-10 | Cantab Pharmaceuticals Research Limited | Defective mutant non-retroviral virus (e.g. HSV) as vaccine |
| US20030083289A1 (en) * | 1995-10-19 | 2003-05-01 | Boursnell Michael Edward Griffith | Herpesvirus vectors and their uses |
| CN1120238C (zh) * | 1998-05-04 | 2003-09-03 | 本元正阳基因技术股份有限公司 | 以粘粒为基础构建重组单纯疱疹病毒及其用途 |
| EP1238086B1 (en) | 1999-12-17 | 2006-03-08 | Wyeth Holdings Corporation | Vaccine for enhancing immune responses to herpes simplex virus |
| WO2005005637A2 (en) * | 2003-05-09 | 2005-01-20 | Medigene, Inc. | Herpes simplex virus comprising a genetically modified glycoprotein d |
| US6984492B2 (en) * | 2003-09-05 | 2006-01-10 | Talecris Biotherapeutics, Inc. | Methods and compositions for treating herpes infections |
| US20080089910A1 (en) | 2004-06-29 | 2008-04-17 | Visalli Et Al | Attenuated Herpes Simplex Virus Type-2, Vectors Thereof and Immunogenic Compositions Thereof |
| CN101390099A (zh) | 2004-07-26 | 2009-03-18 | 皇家飞利浦电子股份有限公司 | 用于模拟执行可执行临床指引的决策支持系统 |
| US8865185B2 (en) * | 2006-09-08 | 2014-10-21 | The Trustees Of The University Of Pennsylvania | Methods of use for HSV-1 and HSV-2 vaccines |
| CA2663109A1 (en) * | 2006-09-08 | 2008-03-13 | The Trustees Of The University Of Pennsylvania | Hsv-1 and hsv-2 vaccines and methods of use thereof |
| JP6144448B2 (ja) * | 2006-12-28 | 2017-06-07 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 単純ヘルペスウイルス複合サブユニットワクチンおよびその使用方法 |
| DK2240595T4 (da) * | 2008-01-03 | 2019-10-07 | Cornell Res Foundation Inc | Glykosyleret proteinekspression i prokaryoter |
| CN101288770A (zh) * | 2008-03-14 | 2008-10-22 | 浙江省医学科学院 | 新型单纯疱疹病毒ⅱ型dna疫苗 |
| WO2010135749A1 (en) * | 2009-05-22 | 2010-11-25 | Genocea Biosciences Inc. | Herpes simplex virus type2: compositions and methods for eliciting an immune response |
| RU2571223C2 (ru) * | 2009-09-18 | 2015-12-20 | Фронхофер Юэсэй Инк. | Вирусоподобные частицы, содержащие белки-мишени, слитые с белками оболочки растительных вирусов |
| WO2015134368A2 (en) * | 2014-03-03 | 2015-09-11 | Albert Einstein College Of Medicine Of Yeshiva University | Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors |
| US10918712B2 (en) | 2014-03-03 | 2021-02-16 | Albert Einstein College Of Medicine | Passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors |
-
2015
- 2015-03-02 WO PCT/US2015/018272 patent/WO2015134368A2/en not_active Ceased
- 2015-03-02 CN CN201580022222.6A patent/CN106456805B/zh active Active
- 2015-03-02 EP EP15758673.6A patent/EP3113801B1/en active Active
- 2015-03-02 EP EP20195405.4A patent/EP3943106A1/en active Pending
- 2015-03-02 CN CN201911344961.3A patent/CN110938604B/zh active Active
- 2015-03-02 JP JP2016555659A patent/JP6652497B2/ja active Active
- 2015-03-02 AU AU2015225499A patent/AU2015225499B2/en active Active
- 2015-03-02 CA CA2942166A patent/CA2942166A1/en active Pending
-
2016
- 2016-02-04 US US15/015,322 patent/US9999665B2/en active Active
-
2017
- 2017-03-10 US US15/455,495 patent/US10076568B2/en active Active
-
2018
- 2018-06-01 US US15/995,471 patent/US10391165B2/en active Active
-
2019
- 2019-07-30 US US16/526,056 patent/US10751411B2/en active Active
-
2020
- 2020-01-23 JP JP2020009043A patent/JP6844045B2/ja active Active
- 2020-08-10 AU AU2020217310A patent/AU2020217310B2/en active Active
- 2020-08-18 US US16/995,926 patent/US10980874B2/en active Active
-
2021
- 2021-02-24 JP JP2021026943A patent/JP7050193B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020079245A (ja) | 2020-05-28 |
| US10391165B2 (en) | 2019-08-27 |
| WO2015134368A2 (en) | 2015-09-11 |
| CN106456805A (zh) | 2017-02-22 |
| CA2942166A1 (en) | 2015-09-11 |
| AU2020217310B2 (en) | 2023-07-13 |
| CN110938604A (zh) | 2020-03-31 |
| AU2015225499A1 (en) | 2016-10-20 |
| US9999665B2 (en) | 2018-06-19 |
| WO2015134368A3 (en) | 2015-11-26 |
| CN110938604B (zh) | 2024-04-05 |
| CN106456805B (zh) | 2020-01-10 |
| AU2015225499B2 (en) | 2020-05-14 |
| US20200376114A1 (en) | 2020-12-03 |
| JP7050193B2 (ja) | 2022-04-07 |
| US20170202952A1 (en) | 2017-07-20 |
| EP3113801A2 (en) | 2017-01-11 |
| EP3113801A4 (en) | 2017-10-25 |
| EP3113801B1 (en) | 2020-10-07 |
| US20160158343A1 (en) | 2016-06-09 |
| JP2017510262A (ja) | 2017-04-13 |
| US10076568B2 (en) | 2018-09-18 |
| US10751411B2 (en) | 2020-08-25 |
| US10980874B2 (en) | 2021-04-20 |
| JP2021088590A (ja) | 2021-06-10 |
| US20190111127A1 (en) | 2019-04-18 |
| EP3943106A1 (en) | 2022-01-26 |
| AU2020217310A1 (en) | 2020-08-27 |
| JP6844045B2 (ja) | 2021-03-17 |
| US20200023058A1 (en) | 2020-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7050193B2 (ja) | 組換え単純ヘルペスウィルス２（ｈｓｖ－２）ワクチンベクター | |
| US20170028058A1 (en) | Herpes simplex virus vaccines | |
| US10918712B2 (en) | Passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors | |
| JP2024016032A (ja) | 組み換え単純ヘルペスウイルス２（ｈｓｖ－２）ワクチンベクターを使用する免疫の受動伝達 | |
| US20220088185A1 (en) | Passive transfer of immunity using recombinant herpes simplex virus 2 (hsv-2) vaccine vectors | |
| HK40022690B (zh) | 重组单纯疱疹病毒2(hsv-2)疫苗载体 | |
| HK1229721B (zh) | 重组单纯疱疹病毒2(hsv-2)疫苗载体 | |
| WO2023245159A1 (en) | Recombinant herpes simplex virus 2 (hsv-2) vectors and engineered transgenic vero cell lines | |
| HK40022690A (en) | Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors | |
| HK1229721A1 (en) | Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180301 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180301 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190121 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190129 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190422 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190628 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190725 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20191224 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200123 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6652497 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |